Eyenovia’s (NASDAQ:EYEN) quiet period is set to end on Tuesday, March 6th. Eyenovia had issued 2,730,000 shares in its initial public offering on January 25th. The total size of the offering was $27,300,000 based on an initial share price of $10.00. During the company’s quiet period, insiders and underwriters involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Several equities research analysts recently issued reports on the stock. Ladenburg Thalmann Financial Services initiated coverage on shares of Eyenovia in a research report on Tuesday, February 20th. They set a “buy” rating and a $35.00 price objective for the company. Roth Capital initiated coverage on shares of Eyenovia in a research note on Tuesday, February 20th. They issued a “buy” rating and a $20.00 price target for the company.
Shares of Eyenovia (NASDAQ:EYEN) opened at $9.24 on Monday. Eyenovia has a 12-month low of $7.32 and a 12-month high of $10.74.
TRADEMARK VIOLATION WARNING: This piece was originally reported by BBNS and is owned by of BBNS. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://baseballnewssource.com/2018/03/12/eyenovia-incs-quiet-period-will-end-tomorrow-nasdaqeyen/1960091.html.
Eyenovia, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of ophthalmology products utilizing its piezo-print technology to deliver micro-doses of active pharmaceutical ingredients (micro-therapeutics) to the eye. Its product candidates include MicroProst, MicroStat, MicroTears and MicroPine.
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.